Myriad Genetics Statistics
Share Statistics
Myriad Genetics has 91.04M shares outstanding. The number of shares has increased by 1.29% in one year.
| Shares Outstanding | 91.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 87.62M |
| Failed to Deliver (FTD) Shares | 338 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 3.35M, so 3.68% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short % of Shares Out | 3.68% |
| Short % of Float | 3.82% |
| Short Ratio (days to cover) | 3.34 |
Valuation Ratios
The PE ratio is -6.02 and the forward PE ratio is 107.8.
| PE Ratio | -6.02 |
| Forward PE | 107.8 |
| PS Ratio | 2.1 |
| Forward PS | 1.3 |
| PB Ratio | 2.02 |
| P/FCF Ratio | -8.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Myriad Genetics Inc. has an Enterprise Value (EV) of 1.31B.
| EV / Earnings | -4.99 |
| EV / Sales | 1.74 |
| EV / EBITDA | -7.06 |
| EV / EBIT | -5.11 |
| EV / FCF | -7.13 |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.01 |
| Quick Ratio | 1.87 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.69 |
| Cash Flow / Debt | -2.88 |
| Interest Coverage | -88.76 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -27.64%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -27.64% |
| Revenue Per Employee | 278.96K |
| Profits Per Employee | -97.52K |
| Employee Count | 2.70K |
| Asset Turnover | 0.66 |
| Inventory Turnover | 10.74 |
Taxes
| Income Tax | 1.10M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -33.5% in the last 52 weeks. The beta is 1.94, so Myriad Genetics 's price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | -33.5% |
| 50-Day Moving Average | 15.31 |
| 200-Day Moving Average | 22.15 |
| Relative Strength Index (RSI) | 39.57 |
| Average Volume (20 Days) | 963.30K |
Income Statement
In the last 12 months, Myriad Genetics had revenue of 753.20M and earned -263.30M in profits. Earnings per share was -3.18.
| Revenue | 753.20M |
| Gross Profit | 517.00M |
| Operating Income | -257.40M |
| Net Income | -263.30M |
| EBITDA | -186.10M |
| EBIT | -257.40M |
| Earnings Per Share (EPS) | -3.18 |
Balance Sheet
The company has 132.10M in cash and 152.10M in debt, giving a net cash position of -20.00M.
| Cash & Cash Equivalents | 132.10M |
| Total Debt | 152.10M |
| Net Cash | -20.00M |
| Retained Earnings | -629.50M |
| Total Assets | 1.08B |
| Working Capital | 138.90M |
Cash Flow
In the last 12 months, operating cash flow was -110.90M and capital expenditures -73.30M, giving a free cash flow of -184.20M.
| Operating Cash Flow | -110.90M |
| Capital Expenditures | -73.30M |
| Free Cash Flow | -184.20M |
| FCF Per Share | -2.22 |
Margins
Gross margin is 68.64%, with operating and profit margins of -34.17% and -34.96%.
| Gross Margin | 68.64% |
| Operating Margin | -34.17% |
| Pretax Margin | -34.81% |
| Profit Margin | -34.96% |
| EBITDA Margin | -24.71% |
| EBIT Margin | -34.17% |
| FCF Margin | -24.46% |
Dividends & Yields
MYGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -23.25% |
| FCF Yield | -14.79% |
Analyst Forecast
The average price target for MYGN is $21, which is 53.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $21 |
| Price Target Difference | 53.5% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
Stock Splits
The last stock split was on Mar 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 5 |